10 results
8-K
EX-99.1
TXMD
TherapeuticsMD Inc
15 May 23
TherapeuticsMD Announces First Quarter 2023 Financial Results
4:16pm
of $31.1 million, or $3.62 per basic and diluted common share, for the comparable period in 2022.
The Company continues to wind down its former commercial
8-K
EX-99.1
20memk16e5y0e cnn5
7 Apr 23
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
4:41pm
8-K
EX-10.2
hlx0arw
31 May 22
TherapeuticsMD and EW Healthcare Partners
6:47am
- Prev
- 1
- Next